Scarica l'app Stockscreener
14.57
2.21%
-0.33
Dopo l'orario di chiusura:
14.55
-0.02
-0.14%
Mink Therapeutics Inc Borsa (INKT) Ultime notizie
MiNK Therapeutics Cuts Q2 Cash Use 31% - AOL.com
Resistance Break Could Fuel MiNK Therapeutics Inc. Rally2025 Dividend Review & Safe Investment Capital Preservation Plans - newsimpact.co.kr
MiNK Therapeutics upgraded to Buy from Neutral at H.C. Wainwright - MSN
Using portfolio simulators with MiNK Therapeutics Inc. included2025 Big Picture & Long-Term Growth Stock Strategies - Newser
HC Wainwright & Co. Upgrades MiNK Therapeutics to Buy Rating with $35 Price Target - AInvest
MiNK Therapeutics Upgraded to Buy by H.C. Wainwright Amid Upcoming Catalysts - AInvest
MiNK Therapeutics outlines multiple late-stage catalysts and targets Phase II gastric cancer data by end of 2025 while expanding partnerships - MSN
MiNK Therapeutics, Inc. (NASDAQ:INKT) Q2 2025 Earnings Call Transcript - MSN
What momentum shifts mean for MiNK Therapeutics Inc.July 2025 Pullbacks & Capital Efficient Trade Techniques - Newser
MiNK Therapeutics: Strategic Momentum and Capital Raise Potential in a High-Stakes Biotech Landscape - AInvest
How to build a dashboard for MiNK Therapeutics Inc. stockQuarterly Portfolio Summary & Free Real-Time Volume Trigger Notifications - Newser
What institutional flow reveals about MiNK Therapeutics Inc.July 2025 Market Mood & Accurate Intraday Trade Tips - Newser
MiNK Therapeutics reports Q2 EPS ($1.06) vs (73c) last year - MSN
MiNK Therapeutics Shares Rise After HC Wainwright Upgrade - MarketScreener
MiNK Therapeutics shares rise 10.31% intraday after HC Wainwright upgrades to Buy. - AInvest
MiNK Therapeutics shares rise 8.77% intraday after HC Wainwright upgrades to Buy. - AInvest
MiNK Therapeutics: Promising Clinical Trials and Growth Prospects Lead to Buy Rating - TipRanks
HC Wainwright Upgrades MiNK Therapeutics to Buy From Neutral - MarketScreener
MiNK Therapeutics upgraded to Buy from Neutral by HC Wainwright & Co., PT raised to $35. - AInvest
MiNK Therapeutics stock rating upgraded to Buy by H.C. Wainwright on financial results - Investing.com Canada
MiNK Therapeutics Inc (INKT) Q2 2025 Earnings Call Highlights: Strategic Advances and Financial ... By GuruFocus - Investing.com Canada
MiNK Therapeutics Reports Q2 2025 Milestones and Financials - TipRanks
What high frequency data says about MiNK Therapeutics Inc.Trade Analysis Report & Community Consensus Trade Alerts - Newser
MiNK Therapeutics Inc. Recovery Likely Here’s What Data Shows2025 Breakouts & Breakdowns & Free Technical Pattern Based Buy Signals - beatles.ru
Real time alert setup for MiNK Therapeutics Inc. performanceJuly 2025 Drop Watch & Accurate Buy Signal Alerts - Newser
MiNK Therapeutics (INKT) and the Strategic Value of AGENT-797 in Oncology and Immune-Mediated Diseases - AInvest
MiNK Therapeutics Q2 2025: Unraveling Key Contradictions in GvHD and ARDS Trial Strategies - AInvest
MiNK Therapeutics Extends Cash Runway - Nasdaq
MiNK INKT Q2 2025 Earnings Call Transcript - AOL.com
Earnings call transcript: Mink Therapeutics Q2 2025 reveals stock drop amid financial loss - Investing.com Nigeria
Earnings call transcript: Mink Therapeutics Q2 2025 reveals stock drop amid financial loss By Investing.com - Investing.com South Africa
Transcript : MiNK Therapeutics, Inc., Q2 2025 Earnings Call, Aug 14, 2025 - MarketScreener
MiNK Therapeutics Cuts Q2 Cash Use 31% - The Motley Fool
MiNK Therapeutics Reports Clinical and Strategic Milestones and Second Quarter 2025 Results - GlobeNewswire
Key resistance and support levels for MiNK Therapeutics Inc.Portfolio Gains Summary & Breakout Confirmation Alerts - Newser
Relative strength of MiNK Therapeutics Inc. in sector analysisFree Daily Chart Pattern Stock Forecast - Newser
Should I invest in MiNK Therapeutics Inc. before earningsSmart Portfolio Allocation - mustnews.co.kr
Mink Therapeutics Inc expected to post a loss of 55 cents a shareEarnings Preview - TradingView
What makes MiNK Therapeutics Inc. stock price move sharplyFree Expert Verified Stock Trade Ideas - Newser
MiNK Therapeutics INKT 2025Q2 Earnings Preview Downside Concerns Amid Lack of Revenue and Profitability - AInvest
Using Python tools to backtest MiNK Therapeutics Inc. strategiesSafe Entry Strategy with High Win Rate - Newser
Candlestick Reversal Detected on MiNK Therapeutics Inc.’s ChartCapital Growth Entry Forecast Summary - beatles.ru
Is MiNK Therapeutics Inc. the Top Chart Pick This WeekInvestment Playbook for Growing Markets Shared - beatles.ru
MiNK Therapeutics (INKT) Projected to Post Earnings on Thursday - Defense World
How does MiNK Therapeutics Inc. generate profit in a changing economyAchieve breakthrough financial results - Jammu Links News
Should I hold or sell MiNK Therapeutics Inc. stock in 2025High-yield capital appreciation - Jammu Links News
How volatile is MiNK Therapeutics Inc. stock compared to the marketAchieve rapid portfolio appreciation - Jammu Links News
Why is MiNK Therapeutics Inc. stock attracting strong analyst attentionTrack stocks with high upside potential easily - Jammu Links News
What are analysts’ price targets for MiNK Therapeutics Inc. in the next 12 monthsUnlock daily market insights for better trades - Jammu Links News
What are the latest earnings results for MiNK Therapeutics Inc.Consistently exceptional gains - Jammu Links News
Is it the right time to buy MiNK Therapeutics Inc. stockFree Stock Market Trend Analysis - Jammu Links News
1.38%
0.27%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):